Last reviewed · How we verify
MOFEZOLAC — Competitive Intelligence Brief
marketed
mofezolac
Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 1
Pain
Small molecule
Live · refreshed every 30 min
Target snapshot
MOFEZOLAC (MOFEZOLAC).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MOFEZOLAC TARGET | MOFEZOLAC | marketed | mofezolac | Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 1 | 1994-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (mofezolac class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MOFEZOLAC CI watch — RSS
- MOFEZOLAC CI watch — Atom
- MOFEZOLAC CI watch — JSON
- MOFEZOLAC alone — RSS
- Whole mofezolac class — RSS
Cite this brief
Drug Landscape (2026). MOFEZOLAC — Competitive Intelligence Brief. https://druglandscape.com/ci/mofezolac. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab